WHO resumes research on hydroxychloroquine as new corona therapy
As a remedy for a novel coronavirus infectious disease (COVID-19) by the World Health Organization (WHO), which was suspended because of "the risk of death and heart disease is increased when taken."HydroxychloroquineResearch will be resumed.
WHO Director-General's opening remarks at the media briefing on COVID-19-03 June 2020
WHO resumes coronavirus trial on hydroxychloroquine after examining safety issues
WHO resumes hydroxychloroquine study for Covid-19
Hydroxychloroquine has been used as an antimalarial drug, and has been attracting attention as a therapeutic drug for new coronavirus infections. However, due to side effectsSignificant increase in risk of death and heart complicationsMay 25, 2020 (Monday) WHOSuspended research on hydroxychloroquineThen announced.
The study suspension was designed to assess the potential benefits and risks of hydroxychloroquine, and was discontinued in a comment from WHO Executive Secretary Tedros Adamanom published Wednesday, June 3, 2020. Reopening became clear. "The data security monitoring committee reviewed the data and, based on the available data, recommended that the members of the committee have no reason to change the trial." Continues to carefully monitor the safety of all therapeutic agents in the trial."
Based on available data, the #COVID19 Solidarity Trial Data Safety & Monitoring Committee recommended there are no reasons to modify the trial protocol.The Executive Group endorsed the continuation of all arms of the Trial, including the use of hydroxychloroquine. https://t.co/r88DVEvZ3j pic.twitter.com/cYITShxcE7
— Tedros Adhanom Ghebreyesus (@DrTedros) June 3, 2020
In addition, Secretary General Tedros said he plans to test hydroxychloroquine in a study of more than 3,500 patients in 35 countries.